Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Providers select concentrations based on the patients body weight, wellness goals, and overall clinical picture
However, severe, recurrent, or widespread bruising warrants medical review to exclude underlying clotting disorders
Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) receptor which reduces appetite and slows gastric emptying [6] [7] GIP (glucose-dependent insulinotropic polypeptide) receptor which enhances insulin secretion and may improve fat metabolism [9] [10] Glucagon receptor which may increase energy expenditure and, based on early clinical and preclinical data, could promote hepatic fat metabolism This triple-action mechanism sets retatrutide apart from existing approved therapies such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)
22,23 A similar Danish study analysed the trend of prescription of GLP-1RAs between 2014 and 2017
These are self-injected once a week, usually in the abdomen or thigh, using a pre-filled syringe or auto-injector
US$ 21.75
US$ 23.92
US$ 24.90
US$ 28.11
US$ 29.23
